Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.06 USD
-0.01 (-12.50%)
Updated Jun 12, 2024 03:32 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Aridis Pharmaceuticals [ARDS]
Reports for Purchase
Showing records 21 - 40 ( 51 total )
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
4Q20: AR-712 Phase 1/2 Starts in 2H21, Phase 3 AR-301 Data Pushed to 1H22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Healthcare -COVID-19 Therapeutics Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Addressing COVID-19 Variants with an Additional Neutralizing mAb
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
3Q20: AR-711 Into Clinic in 1H21, AR-301 Data at YE21, AR-501 Data in 2H21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
EVENT: COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Inhalable mAb Against SARS-CoV-2 Shows Preclinical Promise in Animals
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Adapting Clinical Programs Well to What a Changed World Allows; Reiterate Buy and $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
FDA Agrees to Streamlined Phase 2a/2b Design to Hasten AR-501 Trial Pace
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Forays Into COVID-19 Could Result in Multiple Near-Term Catalysts; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
2Q20: Trials Progressing Well Despite COVID-19, APEX Speeds Drug Discovery
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Clinical Trials Progressing Well Despite COVID-19, APEX Speeds Discovery
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J